An imaging-driven model for liposomal stability and circulation

Molecular Pharmaceutics

Volumn 7, Issue 1, 2010, Pages 12-21

  Qin, Shengping ^a   Seo, Jai Woong ^a   Zhang, Hua ^a   Qi, Jinyi ^a   Curry, Fitz Roy E ^b   Ferrara, Katherine W ^a  

^a University of California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Imaging driven model; Liposomal stability; Pharmacokinetic model

Indexed keywords

BIS 1,1 (4 SULFOBUTYL)INDOTRICARBOCYANINE 5,5 DICARBOXYLIC ACID; DICARBOXYLIC ACID DERIVATIVE; LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CIRCULATION; COMPARTMENT MODEL; DRUG RELEASE; FEMALE; INTERSTITIUM; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; TEMPERATURE SENSITIVITY; TUMOR;

ANIMALS; CAPILLARY PERMEABILITY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG STABILITY; FEMALE; FLUORESCENT DYES; LIPOSOMES; MICE; MODELS, BIOLOGICAL; MONONUCLEAR PHAGOCYTE SYSTEM; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; PHARMACOKINETICS; POSITRON-EMISSION TOMOGRAPHY;

EID: 76249113472     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900122j     Document Type: Article

References (40)

1. Tashjian, J. A.; Dewhirst, M. W.; Needham, D.; Viglianti, B. L. Rationale for and measurement of liposomal drug delivery with hyperthermia using non-invasive imaging techniques. Int. J. Hyperthermia 2008, 24 (1), 79-90.
2. Senior, J.; Delgado, C.; Fisher, D.; Tilcock, C.; Gregoriadis, G. Influence of Surface Hydrophilicity of Liposomes on Their Interaction with Plasma-Protein and Clearance from the Circulation - Studies with Poly(Ethylene Glycol)-Coated Vesicles. Biochim. Biophys. Acta 1991, 1062 (1), 77-82.
3. Allen, T. M. The Use of Glycolipids and Hydrophilic Polymers in Avoiding Rapid Uptake of Liposomes by the Mononuclear Phagocyte System. Adv. Drug Delivery Rev. 1994, 13 (3), 285-309.
4. Garcia, A. A.; Kempf, R. A.; Rogers, M.; Muggia, F. M. A phase II study of Doxil (liposomal doxorubicin): Lack of activity in poor prognosis soft tissue sarcomas. Ann. Oncol. 1998, 9 (10), 1131-1133.
5. Ellerhorst, J. A.; Bedikian, A.; Ring, S.; Buzaid, A. C.; Eton, O.; Legha, S. S. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. Oncol. Rep. 1999, 6 (5), 1097-1099.
6. Chidiac, T.; Budd, G. T.; Pelley, R.; Sandstrom, K.; McLain, D.; Elson, P.; Crownover, R.; Marks, K.; Muschler, G.; Joyce, M.; Zehr, R.; Bukowski, R. Phase II trial of liposomal doxorubicin (Doxil (R)) in advanced soft tissue sarcomas. Invest. New Drugs 2000, 18 (3), 253-259.
7. Halford, S.; Yip, D.; Karapetis, C. S.; Strickland, A. H.; Steger, A.; Khawaja, H. T.; Harper, P. G. A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma. Ann. Oncol. 2001, 12 (10), 1399-1402.
8. Drummond, D. C.; Meyer, O.; Hong, K. L.; Kirpotin, D. B.; Papahadjopoulos, D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 1999, 51 (4), 691-743.
9. Hauck, M. L.; Larue, S. M.; Petros, W. P.; Poulson, J. M.; Yu, D. H.; Spasojevic, I.; Pruitt, A. F.; Klein, A.; Case, B.; Thrall, D. E.; Needha, D.; Dewhirst, M. W. Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin. Cancer Res. 2006, 12 (13), 4004-4010.
10. Lim, H. J.; Masin, D.; McIntosh, N. L.; Madden, T. D.; Bally, M. B. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J. Pharmacol. Exp. Ther. 2000, 292 (1), 337-345.
11. Kong, G.; Dewhirst, M. W. Hyperthermia and liposomes. Int. J. Hyperthermia 1999, 15 (5), 345-370.
12. Kong, G.; Anyarambhatla, G.; Petros, W. P.; Braun, R. D.; Colvin, O. M.; Needham, D.; Dewhirst, M. W. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: Importance of triggered drug release. Cancer Res. 2000, 60 (24), 6950-6957.
13. Needham, D.; Dewhirst, M. W. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv. Drug Delivery Rev. 2001, 53 (3), 285-305.
14. 64Cu for Positron Emission Tomography (PET) Imaging. Bioconjugate Chem. 2008, 19 (12), 2577-2584.
15. Terpetschnig, E.; Szmacinski, H.; Ozinskas, A.; Lakowicz, J. R. Synthesis of squaraine-N-hydroxysuccinimide esters and their biological application as long-wavelength fluorescent labels. Anal. Biochem. 1994, 217 (2), 197-204.
16. Licha, K.; Riefke, B.; Ntziachristos, V.; Becker, A.; Chance, B.; Semmler, W. Hydrophilic cyanine dyes as contrast agents for near-infrared tumor imaging: synthesis, photophysical properties and spectroscopic in vivo characterization. Photochem. Photobiol. 2000, 72 (3), 392-8.
17. Long, D. F.; Repta, A. J. Cisplatin: chemistry, distribution and biotransformation. Biopharm. Drug Dispos. 1981, 2 (1), 1-16.
18. El-Kareh, A. W.; Secomb, T. W. Theoretical models for drug delivery to solid tumors. Crit. Rev. Biomed. Eng. 1997, 25 (6), 503-571.
19. Strand, S. E.; Zanzonico, P.; Johnson, T. K. Pharmacokinetic Modeling. Med. Phys. 1993, 20 (2), 515-527.
20. Gerlowski, L. E.; Jain, R. K. Physiologically Based Pharmacokinetic Modeling - Principles and Applications. J. Pharm. Sci. 1983, 72 (10), 1103-1127.
21. Himmelstein, K. J.; Lutz, R. J. Review of the Applications of Physiologically Based Pharmacokinetic Modeling. J. Pharmacokinet. Biopharm. 1979, 7 (2), 127-145.
22. Watabe, H.; Ikoma, Y.; Kimura, Y.; Naganawa, M.; Shidahara, M. PET kinetic analysis - compartmental model. Ann. Nucl. Med. 2006, 20 (9), 583-588.
23. Nestorov, I. Whole-body physiologically based pharmacokinetic models. Expert Opin. Drug Metab. Toxicol. 2007, 3 (2), 235-249.
24. Hu, L. J.; Au, J. L. S.; Wientjes, M. G. Computational modeling to predict effect of treatment schedule on drug delivery to prostate in humans. Clin. Cancer Res. 2007, 13 (4), 1278-1287.
25. Aukland, K.; Reed, R. K. Interstitial-Lymphatic Mechanisms in the Control of Extracellular Fluid Volume. Physiol. Rev. 1993, 73 (1), 1-78.
26. Michel, C. C. Transport of macromolecules through microvascular walls. Cardiovasc. Res. 1996, 32 (4), 644-653.
27. Michel, C. C.; Curry, F. E. Microvascular permeability. Physiol. Rev. 1999, 79 (3), 703-761.
28. Dreher, M. R.; Liu, W. G.; Michelich, C. R.; Dewhirst, M. W.; Yuan, F.; Chilkoti, A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst. 2006, 98 (5), 335-344.
29. Rippe, B.; Haraldsson, B. Transport of Macromolecules across Microvascular Walls - the 2-Pore Theory. Physiol. Rev. 1994, 74 (1), 163-219.
30. Pollard, R. E.; Garcia, T. C.; Stieger, S. M.; Ferrara, K. W.; Sadlowski, A. R.; Wisner, E. R. Quantitative evaluation of perfusion and permeability of peripheral tumors using contrast-enhanced computed tomography. Invest. Radiol. 2004, 39 (6), 340-349.
31. Kruger, E. F.; Puchalski, S. M.; Pollard, R. E.; Galuppo, L. D.; Hornof, W. J.; Wisner, E. R. Measurement of equine laminar blood flow and vascular permeability by use of dynamic contrast-enhanced computed tomography. Am. J. Vet. Res. 2008, 69 (3), 371-377.
32. Uematsu, H.; Maeda, M.; Sadato, N.; Matsuda, T.; Ishimori, Y.; Koshimoto, Y.; Yamada, H.; Kimura, H.; Kawamura, Y.; Matsuda, T.; Hayashi, N.; Yonekura, Y.; Ishii, Y. Vascular permeability: Quantitative measurement with double-echo dynamic MR imaging - Theory and clinical application. Radiology 2000, 214 (3), 912-917.
33. Watanabe, K.; Nakagawa, H.; Tsurufuji, S. A New Sensitive Fluorometric Method for Measurement of Vascular-Permeability. J. Pharmacol. Methods 1984, 11 (3), 167-176.
34. Tozer, G. M.; Prise, V. E.; Wilson, J.; Cemazar, M.; Shan, S. Q.; Dewhirst, M. W.; Barber, P. R.; Vojnovic, B.; Chaplin, D. J. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability. Cancer Res. 2001, 61 (17), 6413-6422.
35. Tsuchihashi, M.; Harashima, H.; Kiwada, H. Development of a pharmacokinetic/pharmacodynamic (PK/PD)-simulation system for doxorubicin in long circulating liposomes in mice using peritoneal P388. J. Controlled Release 1999, 61 (1-2), 9-19.
36. Aarons, L. Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. Br. J. Clin. Pharmacol. 2005, 60 (6), 581-583.
37. Wu, N. Z.; Braun, R. D.; Gaber, M. H.; Lin, G. M.; ONg, E. T.; Shan, S. Q.; Papahadjopoulos, D.; Dewhirst, M. W. Simultaneous measurement of liposome extravasation and content release in tumors. Microcirculation-London 1997, 4 (1), 83-101.
38. Allen, T. M.; Hansen, C. B.; Demenezes, D. E. L. Pharmacokinetics of Long-Circulating Liposomes. Adv. Drug Delivery Rev. 1995, 16 (2-3), 267-284.
39. Ponce, A. M.; Viglianti, B. L.; Yu, D. H.; Yarmolenko, P. S.; Michelich, C. R.; Woo, J.; Bally, M. B.; Dewhirst, M. W. Magnetic resonance imaging of temperature-sensitive liposome release: Drug dose painting and antitumor effects. J. Natl. Cancer Inst. 2007, 99 (1), 53-63.
40. Anyarambhatla, G. R.; Needham, D. Enhancement of the phase transition permeability of DPPC liposomes by incorporation of MPPC: A new temperature-sensitive liposome for use with mild hyperthermia. J. Liposome Res. 1999, 9 (4), 491-506.